About Biotech Forums
The Biotech Forum is a bi-monthly event run in partnership with the NC Biotechnology Center. The purpose of the Biotech Forum is to provide a meeting place for entrepreneurs, executives, professionals and academicians actively involved in the biotechnology industry. Each forum consists of a 75 minute panel followed by a networking reception.
CED Biotech Forum: Dec. 5, 2012
The Anatomy of a Deal
Engage with life science industry leaders at the CED Biotech Forum. Listen to their reflections on two of this year's most exciting M&A and licensing deals of the Triangle. Attendees will get valuable insights and hear perspectives from both sides of the table - insights usually shared behind closed doors. Learn first hand how the deal progressed from introduction to term sheets and beyond. Join us on Wednesday, December 5, 2012.
Pre-Registration is now closed. Please register on site
Wednesday, December 5, 2012
5:00 pm - 5:30 pm On-site Registration
5:30 pm - 7:00 pm Program
7:00 pm - 8:00 pm Networking Reception Location:North Carolina Biotechnology Center
- 15 T.W. Alexander Drive, Durham, NC Registration:
CED Members - $20 advance/ $30 on-site
Non-members - $40 advance/$50 on-site
Partner, Corporate Transactions & Securities, International Trade & Customs, Life Sciences, Thompson Hine
Faith is a partner in the firm's Corporate Transactions & Securities practice group and the leader of the firm's Life Sciences group. She focuses her practice on corporate, commercial and securities matters, including strategic transactions and corporate structuring.
For over 20 years, Faith has handled a variety of complex corporate transactions including public and private equity and debt financings, private placements, public offerings, corporate governance, mergers and acquisitions, joint ventures and strategic alliances, and venture capital financing both domestically and internationally. She also has experience representing biotechnology and medical device companies in matters related to technology licensing transactions , sponsored research, follow-on offerings, PIPE financing, and assisting public companies in going private.
Primary industries of her clients have included public and private start-ups and late-stage companies, underwriters and placement agents, as well as life science, biotechnology, internet and high technology companies, wholesale, retail and investment banking companies.
Faith was named a BTI Client Service All-Star in 2006 and 2007.
Faith is admitted to practice in the state of New York.
Vice President, Corporate Development
Liquidia Technologies, Inc.
Mr. Chenet joined Liquidia in 2007 from Biolex Therapeutics where he was focused on executing new partnerships with pharmaceutical companies intent on leveraging Biolex' protein engineering and production technology to enable new therapeutic protein products. Prior to joining Biolex, Mr. Chenet was a Director in GlaxoSmithKline's Worldwide Business Development where he was responsible for evaluating and negotiating worldwide licensing agreements across multiple therapeutics areas. Prior to GSK, Mr. Chenet spent several years as a manager at Abbott Laboratories. Mr. Chenet has a M.B.A. from Stanford University and a B.S.E from the University of Michigan.
Jennifer B. Johnson
Director, Worldwide Business Development (WWBD), Transactions and Investment Management
Jennifer B. Johnson is a Director of Worldwide Business Development (WWBD) Transactions and Investment Management at GlaxoSmithKline (GSK). In this capacity, she is part of a global team that is responsible for GSK’s business development deals including in-licenses, out-licenses, research collaborations, co-development and co-promotion arrangements, joint ventures, product acquisitions, newco startups, equity investments and M&A deals. She is also part of the team that is responsible for managing GSK’s portfolio of equity investments in R&D collaboration partners and GSK’s portfolio of LP investments in venture capital funds.
Jennifer has been with GSK for six years in various roles within Corporate, R&D Finance and WWBD. Prior to joining GSK, Jennifer spent over six years in public accounting and consulting roles where she focused on a number of pharmaceutical and biotech clients as well advising on business plan preparations for potential start-up companies. Jennifer serves on the Advisory Board of the Longwood Founder Fund and Hatteras Ventures and is based in RTP, NC. Jennifer holds a Bachelor of Science degree in Accounting with an emphasis in Financial Analysis from North Carolina State University, is a member of the Licensing Executives Society and is a Certified Public Accountant.
Dr. Sanjeev Munshi
Director, External Research and Licensing,
Merck Research Laboratories
Dr. Sanjeev Munshi is a Director in the External Research and Licensing organization of the Merck Research Laboratories. Sanjeev's role is to identify partnering opportunities that fit with Merck's strategic research and development goals across all therapeutic and technology areas. Sanjeev is primarily responsible for scouting and managing alliances in the Southeastern and Mid-Atlantic US.
Sanjeev earned his Ph.D. in molecular biophysics (structural biology) from Indian Institute of Science, India and MBA from Villanova School of Business. Following a postdoctoral fellowship in structural virology at Purdue University, Sanjeev joined MRL at West Point, in 1995. After fifteen years of preclinical drug discovery research, Sanjeev moved into External Scientific Affairs in 2010. Sanjeev is based in Chapel Hill, North Carolina.
President and CEO,
Kenneth Moch joined Chimerix in 2009 as COO and was named President and CEO in April 2010. He brings more than 30 years of experience in building biomedical companies. Prior to joining Chimerix, Mr. Moch founded Euclidean Life Science Advisors and concurrently served as President and CEO of BioMedical Enterprises, Inc. Previously, he was Managing Director, Healthcare Investment Banking, of ThinkEquity Partners. From 1998 to 2006 Mr. Moch served as President and CEO of Alteon Inc., a developer of small molecule therapeutics for cardiovascular aging and diabetic complications, having joined in 1995 as SVP, Finance and Business Development & CFO. As President and CEO of Biocyte Corporation, Mr. Moch pioneered the storage and therapeutic use of cord blood stem cells and launched the first cord blood stem cell storage bank. Earlier in his career, Mr. Moch was a co-founder and Vice President of The Liposome Company, Inc., and a management consultant with McKinsey & Company, Inc.
Mr. Moch currently serves on the Board of the Biotechnology Industry Organization (BIO) and as Secretary of BIO’s Emerging Companies Section. He is a past Chairman of the Biotechnology Council of New Jersey and a past Director of the New York Biotechnology Association. He is a member of the Board of M2Gen/Moffitt Genetics Corporation, a for-profit partnership between Merck and the Moffitt Cancer Center. Mr. Moch holds an A.B. in biochemistry from Princeton University and an MBA from the Stanford University Graduate School of Business.
Previous Biotech Forum: The Campbell Alliance Dealmakers' Intentions Survey
Following a highly successful Super Session at the BIO International Convention, Campbell Alliance is pleased to present the results of its fourth annual Dealmakers’ Intentions Survey, the only forward-looking measure of deal-making activity in the pharmaceutical and biotech industries. While there are many quality sources of information that look historically at past deal trends, this survey offers a prospective view of the partnering and licensing landscape for the year ahead.
In 2012, in-licensers are pushing risk down the food chain to out-licensers. Supply and demand is skewed heavily toward in-licensers demanding de-risked, late-stage assets in the most established therapeutic areas.
However, the number of de-risked assets is relatively lacking, making the 2012 licensing environment a scary one. Discount rates have been rising, which is driving the in-licensers to chase late-stage assets. For those who can accept a long investment horizon in the face of these pressures, a relative surplus of early-stage oncology assets may exist, representing true buying opportunities. Buying opportunities in off-the-beaten-path asset classes may also exist, especially for those in development stages. In short, safety will be expensive in 2012 and into 2013.
Please join us for an in-depth presentation of the full survey results—including an opportunity for questions—where these issues and others will be addressed. A comprehensive white paper summarizing the results will be distributed onsite at the event. Featured Speakers
- Jeff Stewart, Associate Practice Executive, Campbell Alliance